Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Female Sexual Dysfunction Pipeline Drugs Market Report Overview

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

The female sexual dysfunction pipeline drugs market research report provides comprehensive information on the therapeutics under development for female sexual dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for female sexual dysfunction and features dormant and discontinued projects.

Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Targets

The key targets in the female sexual dysfunction pipeline drugs market are Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C among others. The Androgen Receptor is the leading target in the pipeline.

Female Sexual Dysfunction Pipeline Drugs Market Analysis by Targets

Female Sexual Dysfunction Pipeline Products Market Analysis by TargetsFor more target insights into the female sexual dysfunction pipeline drugs market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the female sexual dysfunction pipeline products market are Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist among others. Androgen Receptor Agonist is the leading MoA in the pipeline market.

Female Sexual Dysfunction Pipeline Products Market Analysis by Mechanisms of Action

Female Sexual Dysfunction Pipeline Products Market Analysis by Mechanisms of ActionFor more mechanisms of action insights into the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the female sexual dysfunction pipeline products market are oral, subcutaneous, nasal, topical, vaginal, and sublingual among others. Oral is the leading RoA.

Female Sexual Dysfunction Pipeline Products Market Analysis by Routes of Administration

Female Sexual Dysfunction Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the female sexual dysfunction pipeline drugs market are small molecule, synthetic peptides, cell therapy, and peptide. Small molecule is the leading molecule type.

Female Sexual Dysfunction Pipeline Drugs Market Analysis by Molecule Types

Female Sexual Dysfunction Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the female sexual dysfunction pipeline drugs market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market - Competitive Landscape

Some of the leading companies in the female sexual dysfunction pipeline products market are S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc among others. S1 Biopharma Inc is the leading company in the female sexual dysfunction pipeline products market.

Female Sexual Dysfunction Pipeline Products Market Analysis by Companies

Female Sexual Dysfunction Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the female sexual dysfunction pipeline products market, download a free report sample

Female Sexual Dysfunction Pipeline Products Market Report Overview

Key Targets Androgen Receptor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, D2 Dopamine Receptor, Melanocortin Receptor 4, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 2C
Key Mechanisms of Action Androgen Receptor Agonist, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Melanocortin Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, and Adenosine Receptor A3 Agonist
Key Routes of Administration Oral, Subcutaneous, Nasal, Topical, Vaginal, and Sublingual
Key Molecule Type Small Molecule, Synthetic Peptide, Cell Therapy, and Peptide
Leading Companies S1 Biopharma Inc, Freya Pharma Solutions BV, Jupiter Wellness Inc, Kuhnil Pharmaceutical Co Ltd, Palatin Technologies Inc, Thomas Advanced Medical LLC, Autotelic Bio Inc, and Callitas Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of female sexual dysfunction.
  • The pipeline guide reviews pipeline therapeutics for female sexual dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in female sexual dysfunction therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates female sexual dysfunction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for female sexual dysfunction

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for female sexual dysfunction.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the female sexual dysfunction pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Autotelic Bio Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Endoceutics Inc
Freya Pharma Solutions BV
Jupiter Wellness Inc
Kuhnil Pharmaceutical Co Ltd
Lennham Pharmaceuticals Inc
Palatin Technologies Inc
S1 Biopharma Inc
TherapeuticsMD Inc
Thomas Advanced Medical LLC
Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Sexual Dysfunction – Overview

Female Sexual Dysfunction – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction – Companies Involved in Therapeutics Development

Autotelic Bio Inc

Callitas Therapeutics Inc

Can-Fite BioPharma Ltd

Dare Bioscience Inc

Endoceutics Inc

Freya Pharma Solutions BV

Jupiter Wellness Inc

Kuhnil Pharmaceutical Co Ltd

Lennham Pharmaceuticals Inc

Palatin Technologies Inc

S1 Biopharma Inc

TherapeuticsMD Inc

Thomas Advanced Medical LLC

Viramal Ltd

Female Sexual Dysfunction – Drug Profiles

(buspirone hydrochloride + testosterone) – Drug Profile

Product Description

Mechanism Of Action

(sildenafil citrate + testosterone) – Drug Profile

Product Description

Mechanism Of Action

apomorphine – Drug Profile

Product Description

Mechanism Of Action

bremelanotide acetate – Drug Profile

Product Description

Mechanism Of Action

estradiol – Drug Profile

Product Description

Mechanism Of Action

JW-500 – Drug Profile

Product Description

Mechanism Of Action

KI-1120 – Drug Profile

Product Description

Mechanism Of Action

KI-1128 – Drug Profile

Product Description

Mechanism Of Action

phenylephrine – Drug Profile

Product Description

Mechanism Of Action

prasterone – Drug Profile

Product Description

Mechanism Of Action

Prime Msk Shot – Drug Profile

Product Description

Mechanism Of Action

PrimePro – Drug Profile

Product Description

Mechanism Of Action

S1B-3006 – Drug Profile

Product Description

Mechanism Of Action

S1B-307 – Drug Profile

Product Description

Mechanism Of Action

sildenafil citrate – Drug Profile

Product Description

Mechanism Of Action

SIP-104 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Target A3AR for Sexual Dysfunction – Drug Profile

Product Description

Mechanism Of Action

tadalafil – Drug Profile

Product Description

Mechanism Of Action

testosterone – Drug Profile

Product Description

Mechanism Of Action

testosterone – Drug Profile

Product Description

Mechanism Of Action

Female Sexual Dysfunction – Dormant Projects

Female Sexual Dysfunction – Discontinued Products

Female Sexual Dysfunction – Product Development Milestones

Featured News & Press Releases

Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting

Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting

Oct 17, 2022: Palatin announces publication of Vyleesi (bremelanotide) fMRI study in Women with Hypoactive Sexual Desire Disorder (HSDD)

Oct 10, 2022: Female sexual interest drug reaches tipping point with Phase III plans

Sep 28, 2022: Freya Pharma Solutions receives early EMA scientific advice on its upcoming phase 3 clinical trial to confirm efficacy of Lybrido in women suffering from FSIAD

Aug 29, 2022: Daré Bioscience announces interim analysis of phase 2b RESPOND Study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder

Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter

Jun 29, 2022: Freya Pharma solutions announced its application for EMA scientific advice on its phase 3 clinical trial to confirm efficacy of lybrido in women suffering from FSIAD

Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)

Mar 24, 2021: Daré Bioscience announces initiation of phase 2b RESPOND study of sildenafil cream, 3.6% in women with female sexual arousal disorder

Aug 25, 2020: Knight and TherapeuticsMD announce Health Canada approval of IMVEXXY

Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder

Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder

Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Female Sexual Dysfunction, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Female Sexual Dysfunction – Pipeline by Autotelic Bio Inc, 2022

Female Sexual Dysfunction – Pipeline by Callitas Therapeutics Inc, 2022

Female Sexual Dysfunction – Pipeline by Can-Fite BioPharma Ltd, 2022

Female Sexual Dysfunction – Pipeline by Dare Bioscience Inc, 2022

Female Sexual Dysfunction – Pipeline by Endoceutics Inc, 2022

Female Sexual Dysfunction – Pipeline by Freya Pharma Solutions BV, 2022

Female Sexual Dysfunction – Pipeline by Jupiter Wellness Inc, 2022

Female Sexual Dysfunction – Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022

Female Sexual Dysfunction – Pipeline by Lennham Pharmaceuticals Inc, 2022

Female Sexual Dysfunction – Pipeline by Palatin Technologies Inc, 2022

Female Sexual Dysfunction – Pipeline by S1 Biopharma Inc, 2022

Female Sexual Dysfunction – Pipeline by TherapeuticsMD Inc, 2022

Female Sexual Dysfunction – Pipeline by Thomas Advanced Medical LLC, 2022

Female Sexual Dysfunction – Pipeline by Viramal Ltd, 2022

Female Sexual Dysfunction – Dormant Projects, 2022

Female Sexual Dysfunction – Dormant Projects, 2022 (Contd..1)

Female Sexual Dysfunction – Dormant Projects, 2022 (Contd..2)

Female Sexual Dysfunction – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Female Sexual Dysfunction, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Female Sexual Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.